Skip to main content
Top
Published in: Journal of Neurology 1/2016

01-01-2016 | Original Communication

The pattern of gray matter atrophy in Parkinson’s disease differs in cortical and subcortical regions

Authors: Mechelle M. Lewis, Guangwei Du, Eun-Young Lee, Zeinab Nasralah, Nicholas W. Sterling, Lijun Zhang, Daymond Wagner, Lan Kong, Alexander I. Tröster, Martin Styner, Paul J. Eslinger, Richard B. Mailman, Xuemei Huang

Published in: Journal of Neurology | Issue 1/2016

Login to get access

Abstract

Cortical and subcortical gray matter (GM) atrophy may progress differently during the course of Parkinson’s disease (PD). We delineated and compared the longitudinal pattern of these PD-related changes. Structural MRIs and clinical measures were obtained from 76 PD with different disease durations and 70 Controls at baseline, 18-, and 36 months. Both cortical and subcortical (putamen, caudate, and globus pallidus) GM volumes were obtained, compared, and associated with PD clinical measures at baseline. Their volumes and rates of change also were compared among Controls, PDs, and PD subgroups based on duration of illness [≤1 year (PDE), 1–5 years (PDM), and >5 years (PDL)]. Compared to Controls, PD subjects displayed smaller cortical GM and striatal (putamen, caudate, ps ≤0.001), volumes at baseline. Cortical GM volumes were negatively associated with disease duration at baseline, whereas striatal volumes were not. PD subjects demonstrated accelerated volume loss in cortical GM (p = 0.006), putamen (p = 0.034), and caudate (p = 0.008) compared to Controls. Subgroup analyses demonstrated that accelerated cortical atrophy reached statistical significance in PD subjects with duration of illness 1–5 years (PDM, ps <0.001) and the trend of accelerated atrophy seemed to persist until later stages, whereas striatal atrophy occurred in PD subjects with PDE (p = 0.021 for putamen, p = 0.005 for caudate) and PDM (p = 0.002 for putamen, p = 0.001 for caudate) that significantly slowed down in PDL (ps for PDL vs PDE or PDM: <0.01). The pattern of GM loss in PD differs in cortical and subcortical regions, with striatal atrophy occurring earlier and extra-striatal cortical atrophy later.
Appendix
Available only for authorised users
Literature
1.
go back to reference Braak H, Del Tredici K, Rub U, de Vos RA, Steur ENJ, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed Braak H, Del Tredici K, Rub U, de Vos RA, Steur ENJ, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed
2.
go back to reference Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ et al (2012) Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry 83(2):188–194CrossRefPubMed Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ et al (2012) Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry 83(2):188–194CrossRefPubMed
3.
go back to reference Martin WR, Wieler M, Gee M, Camicioli R (2009) Temporal lobe changes in early, untreated Parkinson’s disease. Mov Disord 24(13):1949–1954CrossRefPubMed Martin WR, Wieler M, Gee M, Camicioli R (2009) Temporal lobe changes in early, untreated Parkinson’s disease. Mov Disord 24(13):1949–1954CrossRefPubMed
4.
go back to reference Gerrits NJ, van der Werf YD, Hofman M, Foncke EM, Klein M, Berendse HW et al (2014) Gray matter differences contribute to variation in cognitive performance in Parkinson’s disease. Eur J Neurol 21(2):245–252CrossRefPubMed Gerrits NJ, van der Werf YD, Hofman M, Foncke EM, Klein M, Berendse HW et al (2014) Gray matter differences contribute to variation in cognitive performance in Parkinson’s disease. Eur J Neurol 21(2):245–252CrossRefPubMed
5.
go back to reference Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, Brooks DJ (2001) Correlating rates of cerebral atrophy in Parkinson’s disease with measures of cognitive decline. J Neural Transm 108(5):571–580CrossRefPubMed Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder GM, Brooks DJ (2001) Correlating rates of cerebral atrophy in Parkinson’s disease with measures of cognitive decline. J Neural Transm 108(5):571–580CrossRefPubMed
6.
go back to reference Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F et al (2012) Progression of cortical thinning in early Parkinson’s disease. Mov Disord 27(14):1746–1753CrossRefPubMed Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F et al (2012) Progression of cortical thinning in early Parkinson’s disease. Mov Disord 27(14):1746–1753CrossRefPubMed
7.
go back to reference Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ et al (2015) Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain 138(Pt 10):2974–2986PubMedCentralCrossRefPubMed Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ et al (2015) Baseline and longitudinal grey matter changes in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain 138(Pt 10):2974–2986PubMedCentralCrossRefPubMed
8.
go back to reference Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC (2006) Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 129(Pt 4):1040–1049CrossRefPubMed Paviour DC, Price SL, Jahanshahi M, Lees AJ, Fox NC (2006) Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain 129(Pt 4):1040–1049CrossRefPubMed
9.
go back to reference Camicioli R, Sabino J, Gee M, Bouchard T, Fisher N, Hanstock C et al (2011) Ventricular dilatation and brain atrophy in patients with Parkinson’s disease with incipient dementia. Mov Disord 26(8):1443–1450CrossRefPubMed Camicioli R, Sabino J, Gee M, Bouchard T, Fisher N, Hanstock C et al (2011) Ventricular dilatation and brain atrophy in patients with Parkinson’s disease with incipient dementia. Mov Disord 26(8):1443–1450CrossRefPubMed
10.
go back to reference Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301CrossRefPubMed Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114(Pt 5):2283–2301CrossRefPubMed
11.
go back to reference Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455CrossRefPubMed Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20(4):415–455CrossRefPubMed
12.
go back to reference Schulzer M, Lee CS, Mak EK, Vingerhoets FJ, Calne DB (1994) A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 117(Pt 3):509–516CrossRefPubMed Schulzer M, Lee CS, Mak EK, Vingerhoets FJ, Calne DB (1994) A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 117(Pt 3):509–516CrossRefPubMed
13.
go back to reference Halliday GM, McCann H (2010) The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci 1184:188–195CrossRefPubMed Halliday GM, McCann H (2010) The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci 1184:188–195CrossRefPubMed
14.
go back to reference Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33–39CrossRefPubMed Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56(1):33–39CrossRefPubMed
15.
go back to reference Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 32(3):489–502CrossRefPubMed Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 32(3):489–502CrossRefPubMed
17.
go back to reference Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170CrossRefPubMed Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23(15):2129–2170CrossRefPubMed
18.
go back to reference Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T et al (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7(1):2–13CrossRefPubMed Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T et al (1992) Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 7(1):2–13CrossRefPubMed
19.
go back to reference Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRefPubMed Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25(15):2649–2653CrossRefPubMed
20.
go back to reference Ruigrok AN, Salimi-Khorshidi G, Lai MC, Baron-Cohen S, Lombardo MV, Tait RJ et al (2014) A meta-analysis of sex differences in human brain structure. Neurosci Biobehav Rev 39:34–50PubMedCentralCrossRefPubMed Ruigrok AN, Salimi-Khorshidi G, Lai MC, Baron-Cohen S, Lombardo MV, Tait RJ et al (2014) A meta-analysis of sex differences in human brain structure. Neurosci Biobehav Rev 39:34–50PubMedCentralCrossRefPubMed
21.
go back to reference Du G, Lewis MM, Sen S, Wang J, Shaffer ML, Styner M et al (2012) Imaging nigral pathology and clinical progression in Parkinson’s disease. Mov Disord 27(13):1636–1643PubMedCentralCrossRefPubMed Du G, Lewis MM, Sen S, Wang J, Shaffer ML, Styner M et al (2012) Imaging nigral pathology and clinical progression in Parkinson’s disease. Mov Disord 27(13):1636–1643PubMedCentralCrossRefPubMed
22.
go back to reference Rosenberg-Katz K, Herman T, Jacob Y, Giladi N, Hendler T, Hausdorff JM (2013) Gray matter atrophy distinguishes between Parkinson disease motor subtypes. Neurology 80(16):1476–1484PubMedCentralCrossRefPubMed Rosenberg-Katz K, Herman T, Jacob Y, Giladi N, Hendler T, Hausdorff JM (2013) Gray matter atrophy distinguishes between Parkinson disease motor subtypes. Neurology 80(16):1476–1484PubMedCentralCrossRefPubMed
23.
go back to reference Fioravanti V, Benuzzi F, Codeluppi L, Contardi S, Cavallieri F, Nichelli P et al (2015) MRI correlates of Parkinson’s disease progression: a voxel based morphometry study. Parkinsons Dis 2015:378032PubMedCentralPubMed Fioravanti V, Benuzzi F, Codeluppi L, Contardi S, Cavallieri F, Nichelli P et al (2015) MRI correlates of Parkinson’s disease progression: a voxel based morphometry study. Parkinsons Dis 2015:378032PubMedCentralPubMed
24.
go back to reference Weintraub D, Dietz N, Duda JE, Wolk D, Doshi J, Xie SX et al (2012) Alzheimer’s disease pattern of brain atrophy predicts cognitive decline in Parkinson’s disease. Brain J Neurol 135(Pt 1):170–180CrossRef Weintraub D, Dietz N, Duda JE, Wolk D, Doshi J, Xie SX et al (2012) Alzheimer’s disease pattern of brain atrophy predicts cognitive decline in Parkinson’s disease. Brain J Neurol 135(Pt 1):170–180CrossRef
25.
go back to reference Kato S, Watanabe H, Senda J, Hirayama M, Ito M, Atsuta N et al (2012) Widespread cortical and subcortical brain atrophy in Parkinson’s disease with excessive daytime sleepiness. J Neurol 259(2):318–326CrossRefPubMed Kato S, Watanabe H, Senda J, Hirayama M, Ito M, Atsuta N et al (2012) Widespread cortical and subcortical brain atrophy in Parkinson’s disease with excessive daytime sleepiness. J Neurol 259(2):318–326CrossRefPubMed
26.
go back to reference Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V et al (2014) Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain 137(Pt 4):1120–1129CrossRefPubMed Hanganu A, Bedetti C, Degroot C, Mejia-Constain B, Lafontaine AL, Soland V et al (2014) Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson’s disease longitudinally. Brain 137(Pt 4):1120–1129CrossRefPubMed
27.
go back to reference Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X (2014) Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease. Mov Disord 29(9):1205–1208PubMedCentralCrossRefPubMed Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X (2014) Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease. Mov Disord 29(9):1205–1208PubMedCentralCrossRefPubMed
28.
go back to reference Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381CrossRefPubMed Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381CrossRefPubMed
29.
go back to reference Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, et al (2010) Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 33(11):3423–3433CrossRef Peran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, et al (2010) Magnetic resonance imaging markers of Parkinson’s disease nigrostriatal signature. Brain 33(11):3423–3433CrossRef
30.
go back to reference Middleton FA, Strick PL (2000) Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Brain Res Rev 31(2–3):236–250CrossRefPubMed Middleton FA, Strick PL (2000) Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Brain Res Rev 31(2–3):236–250CrossRefPubMed
31.
go back to reference Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S et al (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117(Pt 3):501–507CrossRefPubMed Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S et al (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117(Pt 3):501–507CrossRefPubMed
32.
go back to reference Rossi C, Frosini D, Volterrani D, De FP, Unti E, Nicoletti V et al (2010) Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur J Neurol 17(4):626–630CrossRefPubMed Rossi C, Frosini D, Volterrani D, De FP, Unti E, Nicoletti V et al (2010) Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. Eur J Neurol 17(4):626–630CrossRefPubMed
33.
go back to reference Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8(12):1158–1171CrossRefPubMed Maetzler W, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8(12):1158–1171CrossRefPubMed
35.
go back to reference Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53(Suppl 3):S3–S12CrossRefPubMed Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53(Suppl 3):S3–S12CrossRefPubMed
36.
go back to reference Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S et al (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117(Pt 3):501–507CrossRefPubMed Lee CS, Schulzer M, Mak EK, Snow BJ, Tsui JK, Calne S et al (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117(Pt 3):501–507CrossRefPubMed
37.
go back to reference Lee CS, Schulzer M, Fuente-Fernandez R, Mak E, Kuramoto L, Sossi V et al (2004) Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 61(12):1920–1925CrossRefPubMed Lee CS, Schulzer M, Fuente-Fernandez R, Mak E, Kuramoto L, Sossi V et al (2004) Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. Arch Neurol 61(12):1920–1925CrossRefPubMed
Metadata
Title
The pattern of gray matter atrophy in Parkinson’s disease differs in cortical and subcortical regions
Authors
Mechelle M. Lewis
Guangwei Du
Eun-Young Lee
Zeinab Nasralah
Nicholas W. Sterling
Lijun Zhang
Daymond Wagner
Lan Kong
Alexander I. Tröster
Martin Styner
Paul J. Eslinger
Richard B. Mailman
Xuemei Huang
Publication date
01-01-2016
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 1/2016
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7929-7

Other articles of this Issue 1/2016

Journal of Neurology 1/2016 Go to the issue